Publication Name	World Journal of Gastroenterology
Manuscript ID	98642
Country	China

Received	2024-08-08 08:40
Peer-Review Started	2024-08-08 08:40
To Make the First Decision
Return for Revision	2024-08-26 10:17
Revised	2024-09-07 16:33
Second Decision	2024-09-23 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-23 06:00
Articles in Press	2024-09-23 06:00
Publication Fee Transferred	2024-09-26 12:38
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-10-13 16:42
Publish the Manuscript Online	2024-10-16 06:29

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Clinical Trials Study
Article Title	Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Ying Kong, Qi Dong, Peng Jin, Ming-Yan Li, Li Ma, Qi-Jun Yi, Yu-E Miao, Hai-Yan Liu and Jian-Gang Liu
Funding Agency and Grant Number	Funding Agency Grant Number China Scientific Research Fund for HER2 Target from China Anti-Cancer Association CORP-239-M9
Corresponding Author	Hai-Yan Liu, MD, Chief Physician, Professor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 366 Taishan Street, Tai’an 271000, Shandong Province, China. liuhaiyan@sdfmu.edu.cn
Key Words	Human epidermal growth factor receptor 2-positive; Advanced gastric cancer; Inetetamab; Trastuzumab; Efficacy; Safety
Core Tip	Trastuzumab combined with the S-1 plus oxaliplatin (SOX) regimen is the standard first-line treatment for human epidermal growth factor receptor 2-positive advanced gastric cancer. This study demonstrated that the efficacy of inetetamab combined with the SOX regimen is similar to that of trastuzumab combined with the SOX regimen, and the inetetamab group exhibited superior progression-free survival without any additional adverse events.
Publish Date	2024-10-16 06:29
Citation	<p>Kong Y, Dong Q, Jin P, Li MY, Ma L, Yi QJ, Miao YE, Liu HY, Liu JG. Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. <i>World J Gastroenterol</i> 2024; 30(40): 4367-4375</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i40/4367.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i40.4367

Full Article (PDF)	WJG-30-4367-with-cover.pdf
CONSORT 2010 Statement	98642-CONSORT-2010-statement.pdf
Manuscript File	98642_Auto_Edited_013538.docx
Answering Reviewers	98642-answering-reviewers.pdf
Audio Core Tip	98642-audio.mp3
Biostatistics Review Certificate	98642-biostatistics-statement.pdf
Clinical Trial Registration Statement	98642-clinical-trial-registration-statement.pdf
Conflict-of-Interest Disclosure Form	98642-conflict-of-interest-statement.pdf
Copyright License Agreement	98642-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	98642-foundation-statement.pdf
Signed Informed Consent Form(s) or Document(s)	98642-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	98642-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	98642-non-native-speakers.pdf
Peer-review Report	98642-peer-reviews.pdf
Scientific Misconduct Check	98642-scientific-misconduct-check.png
Scientific Editor Work List	98642-scientific-editor-work-list.pdf
CrossCheck Report	98642-crosscheck-report.pdf